Edward M. Basile Sells 5,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director Edward M. Basile sold 5,000 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director now owns 2,866 shares of the company's stock, valued at approximately $362,405.70. This represents a 63.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

TransMedics Group Stock Performance

NASDAQ:TMDX traded up $0.25 during trading hours on Friday, hitting $127.94. 775,406 shares of the company were exchanged, compared to its average volume of 1,359,032. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of 136.11 and a beta of 1.91. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company's 50 day moving average price is $95.30 and its 200-day moving average price is $78.56.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group's revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.35 EPS. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer lifted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $126.70.

Institutional Trading of TransMedics Group

Large investors have recently made changes to their positions in the business. NBC Securities Inc. purchased a new stake in shares of TransMedics Group in the 1st quarter valued at $25,000. Smartleaf Asset Management LLC boosted its holdings in shares of TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after acquiring an additional 135 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group in the 4th quarter valued at $31,000. Hager Investment Management Services LLC purchased a new stake in shares of TransMedics Group in the 4th quarter valued at $33,000. Finally, Quarry LP boosted its holdings in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.